Cambridge Investment Research Advisors’s FT Vest US Equity Moderate Buffer ETF March GMAR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.09M Buy
92,482
+894
+1% +$39K 0.01% 1158
2026
Q1
$3.82M Buy
91,588
+32,089
+54% +$1.32M 0.01% 1125
2025
Q4
$2.44M Sell
59,499
-2,901
-5% -$117K 0.01% 1370
2025
Q3
$2.5M Sell
62,400
-377
-0.6% -$14.9K 0.01% 1340
2025
Q2
$2.44M Buy
62,777
+47,243
+304% +$1.77M 0.01% 1277
2025
Q1
$578K Buy
15,534
+1,012
+7% +$38.2K ﹤0.01% 2293
2024
Q4
$544K Buy
14,522
+1,162
+9% +$43.2K ﹤0.01% 2360
2024
Q3
$491K Sell
13,360
-18,864
-59% -$677K ﹤0.01% 2429
2024
Q2
$1.14M Buy
32,224
+2,501
+8% +$86.5K ﹤0.01% 1665
2024
Q1
$1.02M Buy
+29,723
New +$1M ﹤0.01% 1717

Other funds holding GMAR

Cambridge Investment Research Advisors's GMAR Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its FT Vest US Equity Moderate Buffer ETF March (GMAR) stake by 0.98% in Q2 2026, buying an estimated $39K and bringing the position to 92,482 shares worth $4.09M. The position accounts for 0.01% of the portfolio, ranked #1158.

Cambridge Investment Research Advisors first reported a position in GMAR in Q1 2024 and has held it in 10 quarters since. 127 funds tracked by Wall St. Rank hold GMAR as of Q2 2026.

  • Cambridge Investment Research Advisors held 92,482 shares of FT Vest US Equity Moderate Buffer ETF March worth $4.09M as of Q2 2026.
  • Cambridge Investment Research Advisors bought 894 FT Vest US Equity Moderate Buffer ETF March shares in Q2 2026, an estimated $39K.
  • FT Vest US Equity Moderate Buffer ETF March made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1158 holding.
  • Cambridge Investment Research Advisors first reported a position in FT Vest US Equity Moderate Buffer ETF March in Q1 2024 and has held it in 10 quarters since.
  • 127 funds tracked by Wall St. Rank held FT Vest US Equity Moderate Buffer ETF March as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.